EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series

Lisha Wu, Huisheng Chen, Zihang Lin, Haiwei Xiao, Tao Qin

Case Reports in Oncology · 08.09.2026 · 19 (1) · 1688-1697

DOI: 10.1159/cro/abzag051 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 08.09.2026. Verfasst von Lisha Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The later-line treatment for advanced solid tumors that have progressed after multiple lines of therapy remains limited and challenging. Utidelone (UTD1), an analog of epothilone B, has shown significant antitumor activity in breast cancer undergone at least one previous chemotherapy in China. However, the combined therapeutic effect of UTD1 and programmed cell death protein-1 (PD-1) inhibitors in heavily pretreated solid tumors is unclear. Case Presentation: Herein, we report a case series of 3 patients with heavily pretreated advanced solid tumors, including nasopharyngeal carcinoma and pulmonary adenocarcinoma, who had progressed after multiple lines of standard therapy. Treatment with UTD1 in combination with PD-1 inhibitors demonstrated promising efficacy. Individual progression-free survival times were 9, 5, and 6 months, respectively, with 2 patients achieving a partial response and one achieving stable disease. Although peripheral neuropathy was a common adverse event, it was generally manageable.

Conclusion

Our case series highlights that UTD1 plus PD-1 inhibitors could become a novel later-line treatment option for patients with advanced solid tumors that have failed multiple standard therapies.

Schlagwörter

Stichwörter der Autor:innen

Case seriesLater-line treatmentPD-1 inhibitorsUtidelone

Autor:innen und Institutionen

  • Department of Oncology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China.
  • Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Traditional Chinese Medicine, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China.

Zitieren

APA

Wu, L., Chen, H., Lin, Z., Xiao, H., & Qin, T. (2026). Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series. Case Reports in Oncology, 19(1), 1688-1697. https://doi.org/10.1159/cro/abzag051

Vancouver

Wu L, Chen H, Lin Z, Xiao H, Qin T. Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series. Case Reports in Oncology. 2026;19(1):1688-1697. doi:10.1159/cro/abzag051

BibTeX
@article{Wu2026,
  author = {Wu, Lisha and Chen, Huisheng and Lin, Zihang and Xiao, Haiwei and Qin, Tao},
  title = {Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {1688--1697},
  doi = {10.1159/cro/abzag051}
}
Kostenlos starten →